AstraZeneca

Phone: +144 (0)20 3749 5000

E-mail: Medical.InformationUK@astrazeneca.com

Type	Public limited company
Traded as	LSE: AZN FTSE 100 component Nasdaq Stockholm: AZN OMX Stockholm 30 component Nasdaq: AZN Nasdaq-100 component
ISIN
Industry	Pharmaceutical Biotechnology
Predecessors	Astra AB Zeneca Group plc
Founded	6 April 1999 (1999-04-06)
Headquarters	1 Francis Crick Avenue, Cambridge, UK
Area served	Global
Key people	Leif Johansson (Chairman) Pascal Soriot (CEO)
Products	Pharmaceutical products
Revenue	US$37.417 billion (2021)
Operating income	US$1.056 billion (2021)
Net income	US$0.115 billion (2021)
Total assets	US$105.363 billion (2021)
Total equity	US$39.287 billion (2021)
Number of employees	76,100 (2020)
Subsidiaries	Alexion Pharmaceuticals MedImmune
Website	www.astrazeneca.com

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.

For detailed contact information visit location pages below.

AstraZeneca's locations around the world

EuropeExpand

North AmericaExpand

AsiaExpand

AfricaExpand

South AmericaExpand

OceaniaExpand

Australia

Clinical Trials sponsored by AstraZeneca

AstraZeneca
AstraZeneca K.K.

Completato

Uno studio per valutare l'AZD2693 nei partecipanti che sono portatori dell'allele di rischio PNPLA3 148M con steatoepatite non alcolica non cirrotica con fibrosi (FORTUNA)

Steatoepatite non alcolica

Stati Uniti, Italia, Tailandia, Germania, Brasile, Cina, Malaysia, Taiwan, Chile, Spagna, Giappone, Hong Kong, Argentina, India, Messico, Vietnam, Singapore, Filippine, Perù, Colombia, Corea del Sud, Turchia (Türkiye)
AstraZeneca
AstraZeneca K.K.

Completato

Una prova per scoprire quale delle 4 diverse dosi di AZD0780 è più sicura e aiuta meglio a trattare le persone con dislipidemia (PURSUIT)

Dislipidemia

Stati Uniti, Canada, Spagna, Ungheria, Cechia, Danimarca, Slovacchia, Giappone
AstraZeneca

Non ancora reclutamento

The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP" (DEBATE)

CRSwNP or CRSsNP Patients
AstraZeneca

Non ancora reclutamento

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)

Diabete mellito di tipo 2 | Type 2 Diabetes With Chronic Kidney Disease

Stati Uniti, Danimarca, Spagna, Taiwan, Tailandia, Vietnam, Germania, Giappone, Messico, Cina, Malaysia, Ucraina, Regno Unito, India, Turchia (Türkiye)
AstraZeneca

Non ancora reclutamento

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus (Eluminate-5)

Diabete mellito di tipo 2

Stati Uniti, Danimarca, Regno Unito, Ungheria, Brasile, Vietnam, Malaysia, Taiwan, Cina, Germania, Grecia, Polonia, Ucraina, Cechia, Giappone, Porto Rico, Argentina, Corea del Sud
AstraZeneca

Non ancora reclutamento

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. (ARGiNAUT)

Fibrosi polmonare idiopatica (IPF)

Stati Uniti, Canada, Danimarca, Germania, Italia, Spagna, Polonia, Francia, Ungheria, Cina, Taiwan, Chile, Argentina, Sud Africa, Giappone, Regno Unito, Grecia, Australia, Israele, Messico, Bulgaria, Corea del Sud
AstraZeneca

Non ancora reclutamento

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

Lupus eritematoso sistemico
AstraZeneca

Reclutamento

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM (ATTRiumph)

Cardiomiopatia amiloide-transtiretina (ATTR-CM)

Spagna, Regno Unito, Stati Uniti, Svezia, Italia, Germania, Francia, Cina, Canada, Giappone
AstraZeneca

Reclutamento

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (MONTEROSA)

Carcinoma epatocellulare

Italia
AstraZeneca

Non ancora reclutamento

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer (PROSPECTOR)

Cancro alla prostata metastatico

Italia, Spagna, Stati Uniti, Germania, Regno Unito, Australia, Corea del Sud

AstraZeneca

AstraZeneca's locations around the world

Clinical Trials sponsored by AstraZeneca

List of Pharmaceutical Companies by location